0001209191-21-015496.txt : 20210301
0001209191-21-015496.hdr.sgml : 20210301
20210301205405
ACCESSION NUMBER: 0001209191-21-015496
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kwan Pui San
CENTRAL INDEX KEY: 0001733642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 21700793
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-25
0
0001340652
ChemoCentryx, Inc.
CCXI
0001733642
Kwan Pui San
C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW
CA
94043
0
1
0
0
Principal Acctg Officer
Common Stock
2021-03-01
4
M
0
1389
10.86
A
4621
D
Common Stock
2021-03-01
4
M
0
1125
11.02
A
5746
D
Common Stock
2021-03-01
4
M
0
833
9.04
A
6579
D
Common Stock
2021-03-01
4
S
0
1530
68.0843
D
5049
D
Common Stock
2021-03-01
4
S
0
1817
68.8862
D
3232
D
Stock Option (right to buy)
65.87
2021-02-25
4
A
0
16640
A
2031-02-25
Common Stock
16640
16640
D
Stock Option (right to buy)
10.86
2021-03-01
4
M
0
1389
D
2028-03-05
Common Stock
1389
13897
D
Stock Option (right to buy)
11.02
2021-03-01
4
M
0
1125
D
2029-03-04
Common Stock
1125
24750
D
Stock Option (right to buy)
9.04
2021-03-01
4
M
0
833
D
2029-11-01
Common Stock
833
25834
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $67.64 to $68.60 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.64 to $69.19 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
The option was granted on February 25, 2021, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
Not applicable.
As of March 1, 2021, and prior to this transaction, the exercised options were fully vested.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2021-03-01